Is Carfilzomib a chemotherapy drug?

Carfilzomib (Carfilzomib) is not a traditional chemotherapy drug, but a targeted therapy drug commonly used to treat multiple myeloma (Multiple Myeloma) and other related blood cancers. Multiple myeloma is a malignant tumor in the leukemia and lymphoma system that is characterized by abnormal proliferation of plasma cells in the bone marrow, leading to damage to the skeletal system.

Unlike traditional chemotherapy drugs, carfilzomib interferes with the survival and proliferation of cancer cells through a specific mechanism, rather than killing cancer cells through toxic effects. Its mechanism of action involves inhibition of the proteasome, a cellular organelle responsible for protein degradation. By blocking the normal function of the proteasome, carfilzomib prevents protein degradation in cancer cells, leading to the accumulation of toxic proteins inside the cancer cells and ultimately the death of the cancer cells. This mechanism of action enables carfilzomib to more precisely interfere with the survival and proliferation of cancer cells, reducing unnecessary damage to healthy cells, thus mitigating adverse side effects during treatment.

Carfilzomib is usually given as an intravenous injection to ensure the drug is effectively delivered to target tissues. Although it has made significant progress in the treatment of multiple myeloma, it may still be accompanied by some specific adverse reactions, such as thrombocytopenia, heart problems, and kidney dysfunction. Therefore, patients usually need to receive treatment under the supervision of a doctor to ensure safety and effectiveness. Overall, carfilzomib represents a modern cancer treatment that has the potential to improve the survival and quality of life of patients with multiple myeloma by precisely intervening in the survival mechanisms of cancer cells.

Carfilzomib has been launched in China and is included in medical insurance. Patients can purchase it domestically at a price of around 8,000 to 9,000 yuan. Please consult the local hospital pharmacy for specific prices. In foreign countries, the original drug of carfilzomib is mainly available, and the cheaper version is the European version of the original drug, which costs around 5,000. And the medicinal ingredients and efficacy are the same as those of domestic original medicines.